Emerging roles of the single EF-hand Ca2+ sensor tescalcin in the regulation of gene expression, cell growth and differentiation by Kolobynina Ksenia Glebovna et al.
COMMENTARY
Emerging roles of the single EF-hand Ca2+ sensor tescalcin in the
regulation of gene expression, cell growth and differentiation
Ksenia G. Kolobynina1, Valeria V. Solovyova1, Konstantin Levay2, Albert A. Rizvanov1 and Vladlen Z. Slepak2,*
ABSTRACT
Tescalcin (TESC, also known as calcineurin-homologous protein 3,
CHP3) is a 24-kDa EF-hand Ca2+-binding protein that has recently
emerged as a regulator of cell differentiation and growth. The TESC
gene has also been linked to human brain abnormalities, and high
expression of tescalcin has been found in several cancers. The
expression level of tescalcin changes dramatically during development
and upon signal-induced cell differentiation. Recent studies have
shown that tescalcin is not only subjected to up- or down-regulation, but
also has an active role in pathways that drive cell growth and
differentiation programs. At the molecular level, there is compelling
experimental evidence showing that tescalcin can directly interact with
and regulate the activities of the Na+/H+ exchanger NHE1, subunit 4 of
the COP9 signalosome (CSN4) and protein kinase glycogen-synthase
kinase 3 (GSK3). In hematopoetic precursor cells, tescalcin has been
shown to couple activation of the extracellular signal-regulated kinase
(ERK) cascade to theexpressionof transcription factors that control cell
differentiation. Thepurposeof thisCommentary is to summarize recent
efforts that have served to characterize the biochemical, genetic and
physiological attributes of tescalcin, and its unique role in the regulation
of various cellular functions.
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Introduction
The role of Са2+ as a universal second messenger often depends on
Ca2+-binding proteins, which regulate the activities of enzymes, ion
channels and other proteins that allow cells to respond to
fluctuations in the concentration of free intracellular Ca2+. The
literature on Ca2+ sensing and signaling is rich, with many excellent
reviews on the physiological role of Ca2+ and information on
hundreds of Ca2+-binding proteins (see e.g. Clapham, 2007; Zhou
et al., 2013). This Commentary draws attention to the relatively
unknown Ca2+-sensor tescalcin, which was discovered as a gene
(TESC) that is differentially expressed in the development of
embryonic mouse testis (Perera et al., 2001). Subsequent
investigations revealed broader expression patterns of TESC, and
have illuminated its crucial role in several important cellular
pathways. Tescalcin is an unusual Ca2+-sensor in that it regulates
relatively slow physiological processes such as cell differentiation.
In contrast, most other Ca2+-sensors are associated with rapid
events, such as muscle contraction or neurotransmitter release
(Clapham, 2007; Zhou et al., 2013). Thus, efforts to understand how
tescalcin extends the duration of transient Ca2+ signals are expected
to provide new insights into the graded signaling mechanisms that
underlie development.
Tescalcin belongs to a large family of Са2+-binding proteins that
contain the EF-hand, a structural motif annotated for the first time in
1973 in parvalbumin (Kretsinger and Nockolds, 1973; Mikhaylova
et al., 2011; Zhou et al., 2013). The canonical EF-hand consists of a
Са2+-binding loop that contains 12 highly conserved residues
flanked by two helices, named as E and F, respectively. There are
also four types of non-canonical EF-hands that have insertions,
deletions or substitutions that fine-tune divalent cation coordination
(Gifford et al., 2007; Lewit-Bentley and Réty, 2000). The
superfamily of EF-hand proteins is divided into two groups. The
first group has a Са2+-binding affinity of below 100 nM and does
not undergo major Са2+-induced conformational changes; these
Са2+-binding proteins are referred to as Са2+ buffers or Са2+
modulators (e.g. parvalbumin and calbindin). The second group is
known as Са2+-sensors. These Са2+-sensing proteins have evolved
to bind Са2+ within the 10−5–10−6 М range and typically exhibit
Са2+-induced conformational changes that influence their
interaction with target proteins (da Silva and Reinach, 1991;
Bhattacharya et al., 2004). An archetypalСа2+ sensor is calmodulin,
which has four EF-hands and regulates a plethora of effectors
(Clapham, 2007). Although Са2+ sensors regulate the activities of
ion channels and enzymes, Са2+ buffers modulate the amplitude
and kinetics of free Са2+ transients and maintain Са2+ homeostasis.
For example,Са2+ buffers keep the concentration of freeСа2+ below
the levels that would induce cell death (Christakos and Liu, 2004;
D’Orlando et al., 2001; Kook et al., 2014). Because the affinity of
tescalcin for Ca2+ is in the micromolar range (Gutierrez-Ford et al.,
2003), it is thought to be a Са2+-sensor.
In this article, we summarize the current insights into cellular
functions of tescalcin, focusing on its unique biochemical properties
and binding partners identified to date, namely, the Na+/H+
exchanger NHE1, glycogen synthase kinase 3 (GSK3) and the
COP9 signalosome. We also discuss its potential physiological role
and the potential association of TESC gene mutations with human
pathologies.
Structural features andmetal-bindingproperties of tescalcin
Tescalcin contains only one canonical EF-hand motif in its
C-terminal half (amino acids 113–142) (Fig. 1). It also has three
additional putative helix-loop-helix motifs that have likely evolved
from EF-hands, but because of substitutions of crucial residues
and insertions, their similarity to the canonical EF-hand is too low
to support chelation of Ca2+ (Gutierrez-Ford et al., 2003). Single
EF-hand proteins are very rare (Day et al., 2002; Huang et al.,
2009; Mochizuki et al., 1996), and in most proteins these domains
are paired, which allows them to bind Ca2+ with higher affinity.
Proteins with an odd number of EF-hand domains are known to
dimerize, so that the non-paired EF-hands of the two subunits
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form a pair (Finn et al., 1992; Gifford et al., 2007; Shaw et al.,
1994). Some proteins with single EF-hands do not chelate Ca2+;
their EF-hand functions instead as a protein–protein interaction
domain. For example, the EF-hand of Nkd signaling proteins can
bind to Drosophila and mouse Desheveled proteins, crucial
participants of the Wnt pathway, in the absence of Ca2+ (Wharton
et al., 2001).
The crucial aspartic acid in the canonical EF-hand of tescalcin,
Asp123 is essential for chelating of Ca2+, and its replacement by
alanine (D123A) eliminates Ca2+ binding and Ca2+-induced
changes in tryptophan fluorescence (Gutierrez-Ford et al., 2003).
According to UV circular dichroism spectrometry, the D123A
mutation does not significantly disturb the overall secondary
structure of the protein (Gutierrez-Ford et al., 2003). However,
when the mutant is overexpressed in CHO-K1, HEK293 or HeLa
cells, it exhibits considerably lower expression levels than wild type,
suggesting that Ca2+ is essential for stabilizing the tescalcin fold. As
discussed below, the D123A mutation has been instrumental in the
functional studies of tescalcin (Kobayashi et al., 2015; Levay and
Slepak, 2014; Zaun et al., 2012).
Tescalcin shares substantial sequence similarity with three other
Ca2+-binding proteins: calcineurin homologous protein 1 (CHP1;
34% identity, 54% similarity), calcineurin homologous protein 2
(CHP2; 29% identity, 48% similarity) and calcineurin B (CnB;
27% identity, 50% similarity). Therefore, sometimes tescalcin is
referred to as CHP3 (Di Sole et al., 2012; Zaun et al., 2008).
However, whereas tescalcin only has one functional EF-hand,
CHP1 and CHP2 have two each and CnB has four (Naoe et al.,
2005) (Fig. 1). Tescalcin contains three unique ‘inserts’ of eight to
nine amino acids each that distinguish it from CHP1 and CHP2.
Two of these inserts break up the sequences in the EF-hands two
and four, apparently contributing to their inactivation. Deletion
mutagenesis data suggest that the unique C-terminus extension of
tescalcin might be necessary for interaction with its downstream
effector CSN4, with which CHP1 and CHP2 do not interact
(Levay and Slepak, 2014).
As determined by direct 45Ca2+ binding and monitoring of Ca2+-
induced changes in the intrinsic tryptophan fluorescence,
recombinant tescalcin binds Ca2+ with stoichiometry close to one
Ca2+ ion per protein and aKd of∼0.8×10−6M (Gutierrez-Ford et al.,
2003). Some EF-hand motifs are promiscuous and are able to bind
other bivalent cations, such as Mg2+ and Zn2+ (Dizhoor et al., 2010;
Donato, 1999). Experiments with recombinant tescalcin indicate
that it can bind Mg2+, but not Zn2+, and might exist in a Mg2+-
associated form in resting cells, shifting to the Ca2+-bound form
during fluxes in Ca2+ (Gutierrez-Ford et al., 2003). Because the Kd
of purified tescalcin for Ca2+ in the presence of Mg2+ is ∼3 μM,
Mg2+ exchange can only occur when (local) Ca2+ concentrations
reach micromolar levels. It appears that in order to detect free Ca2+
in submicromolar concentrations, tescalcin must have higher
affinity for Ca2+. Indeed, the Ca2+ affinity of CHP1 and CHP2 is
significantly higher (90 nM) (Pang et al., 2004). We speculate that
one mechanism to increase the Ca2+ affinity of tescalcin could
involve its dimerization and pairing of the EF-hands. Consistent
with this idea, ∼10% of E.-coli-expressed tescalcin elutes in
fractions that correspond to the molecular mass of its dimer on a gel-
filtration; however, the bulk of the protein runs as a monomer
(Gutierrez-Ford et al., 2003). The peak that corresponds to the dimer
is not observed in the presence of β-mercaptoethanol, indicating
its dependence on a disulfide bond(s). Alternatively, the regions
with low similarity to an EF-hand that are found in tescalcin might
still contribute sites for chelating Ca2+. It is possible that such
CnB     1 MGNEASYPLEMCS--------HFDADEIKRLGKRFKKLDLDNSGSLSVEEFM
CHP1    1 MGSRASTLLRDEELEEIKKETGFSHSQITRLYSRFTSLDKGENGTLSREDFQ
CHP2    1 MGSRSSHAAVIPDGDSIRRETGFSQASLLRLHHRFRALDRNKKGYLSRMDLQ
TESC    1 MGAAHSASEEVRELEG---KTGFSSDQIEQLHRRFKQLS-GDQPTIRKENFN
CnB    45 SLPELQQNPLVQRVIDIFDTDG---------NGEVDFKEFIEGVSQFSVKGD
CHP1   53 RIPELAINPLGDRIINAFFPEG---------EDQVNFRGFMRTLAHFRPIED
CHP2   53 QIGALAVNPLGDRIIESFFPDG---------SQRVDFPGFVRVLAHFRPVED
TESC   48 NVPDLELNPIRSKIVRAFFDNRNLRKGPSGLADEINFEDFLTIMSYFRPIDT
CnB    88 ----------------KEQKLRFAFRIYDMDKDGYISNGELFQVLKMMVGNN
CHP1   96 -NEKSKDVNGPEPLNSRSNKLHFAFRLYDLDKDEKISRDELLQVLRMMVGVN
CHP2   96 EDTETQDPKKPEPLNSRRNKLHYAFQLYDLDRDGKISRHEMLQVLRLMVGVQ
TESC  101 ------TMDEEQVELSRKEKLRFLFHMYDSDSDGRITLEEYRNVVEELLSGN
CnB   124 --LKDTQLQQIVDKTIINAD---------KDGDGRISFEEFCAVVGGLDIHK
CHP1  147 --ISDEQLGSIADRTIQEAD---------QDGDSAISFTEFVKVLEKVDVEQ
CHP2  148 --VTEEQLENIADRTVQEAD---------EDGDGAVSFVEFTKSLEKMDVEQ
TESC  147 PHIEKESARSIADGAMMEAASVCMGQMEPDQVYEGITFEDFLKIWQGIDIET
CnB   165 KMVVDV----------
CHP1  187 KMSIRFLH--------
CHP2  188 KMSIRILK--------
TESC  198 KMHVRFLNMETMALCH
EF-hand 3 
N-myristoylation EF-hand 1 
EF-hand 2 
EF-hand 4 
Fig. 1. Sequences of tescalcin and its close homologs.
Shown here are the amino acid sequences human tescalcin
(Genbank Accession Number AAL35615.1) with CHP1
(NP_009167), CHP2 (NP_071380.1) and calcineurin B (CnB,
AAB08721.1). Sequence alignment was performed using
ClustalW, with BoxShage 3.21 for presentation. Identical
amino acids are shown in dark green; homologous residues
are in teal. The four active EF-hand domains in CnB are
denoted by blue brackets and are numbered. The solid
bracket surrounding the canonical EF-hand 3 indicates that it
is active in tescalcin. The red arrow indicates the position of
the critical D123 residue necessary for Ca2+ binding; the
D123A mutant has been used to study the role of Ca2+ in
tescalcin function (see text). The dashed brackets show the
EF-hands that are inactive in tescalcin. EF-hand 4 is active in
CHP1 and CHP2. The unique amino acid ‘inserts’ found in
tescalcin are highlighted with red frames; these interrupt the
sequences in its homologous EF-hand domains 2 and 4. The
N-myristoylation site, the G2 residue, is indicated by the
arrow.
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mechanisms can be engaged in vivo, and the affinity of tescalcin for
Ca2+ is higher when it is bound to a protein partner, as is the case for
CHP1 when it associates with the Na+/H+ exchanger NHE1 (Pang
et al., 2004).
Tescalcin has an N-myristoylation motif that is also present
in CHP1 and CHP2. N-myristoylation of tescalcin has been
demonstrated by incorporation of [3H]myristate upon co-
expression in E. coli with yeast N-myristoyl transferase-1
(Gutierrez-Ford et al., 2003). This suggests that tescalcin, similar
to some other EF-hand proteins, such as recoverin (Ames et al.,
1994; Ladant, 1995; Zozulya and Stryer, 1992), can undergo a
Са2+-induced myristoyl switch, a conformational change that
facilitates its interaction with membranes and effector proteins.
Binding partners and effectors of tescalcin
NHE1
The interaction of tescalcin with NHE1 was discovered in a yeast
two-hybrid screen utilizing the C-terminal domain of NHE1 as the
bait (Mailänder et al., 2001). The N-terminus of NHE1 contains 12
putative transmembrane domains that form an antiport ion channel,
and its cytosolic C-domain is responsible for interacting with
factors, such as CHP1, CHP2 and tescalcin (Ammar et al., 2006; Di
Sole et al., 2012; Lin and Barber, 1996; Pang et al., 2004).
Activation of NHE1 stimulates the efflux of protons from within the
cell and causes a local rise in internal pH. In general, such pH
increases are associated with increased cell proliferation and
decreased apoptosis. However, considering that pH can influence
signaling pathways by altering protein phosphorylation (Isom et al.,
2013), prediction of the effect a change in pH has in a given
biological system can be challenging.
The structural basis and functional role of the NHE1–tescalcin
interaction has been confirmed and investigated by different
laboratories (Li et al., 2003, 2004; Zaun et al., 2008). According
to the detailed studies of Zaun et al., the amino acid residues of
NHE1 that are necessary for tescalcin binding are also crucial for
binding of CHP1 and CHP2, and their mutation has a profound
effect on the 22Na+/H+ exchange activity. Co-expression of tescalcin
with NHE1 increased the abundance and surface stability of NHE1
in AP-1 cells (Zaun et al., 2008). The authors conclude that tescalcin
stabilizes the mature (i.e. glycosylated) form of NHE1 on the cell
surface, increasing its half-life by approximately threefold. A
subsequent study by the same group showed that both Ca2+ and N-
myristoylation of tescalcin were involved in regulation of NHE1
expression and its ion exchange activity (Zaun et al., 2012).
Specifically, it was shown that protein with a D123A mutation in
conjunction with a G2Amutation, which prevents N-myristoylation
and membrane localization, still interacts with the ion exchanger
NHE1, but reduces its cell surface half-life and transport velocity.
Thus, although Ca2+ is not essential for the interaction between
tescalcin and NHE1, the Ca2+-bound form of tescalcin clearly
regulates NHE1 turnover and activity (Zaun et al., 2012). Overall,
these studies support the notion that tescalcin undergoes a Ca2+–
myristoyl switch, which plays a role in the upregulation of NHE1
activity (Zaun et al., 2012).
It is worth noting that some discrepancies exist with regard to
the described tescalcin–NHE1 interactions, suggesting that the
relationship between tescalcin and NHE1 might be nuanced. To
date, all studies have implicated the C-terminus of NHE1 in the
interaction with tescalcin, but have identified different regions to be
of functional importance, for example, either juxtamembrane sites
(Zaun et al., 2008) or the distant C-tail positions (Li et al., 2003).
The functional effects of the tescalcin–NHE1 interaction are also
being debated, with the former report showing stimulation of NHE1
by tescalcin, whereas the latter demonstrated its suppression. It is
also worth noting that whereas co-expression of tescalcin with
NHE1 in CHO cells results in a redistribution of tescalcin to the
plasma membrane (Zaun et al., 2008), in cardiac myocytes,
tescalcin does not colocalize with NHE1 (Kobayashi et al., 2015).
However, under the same conditions, NHE1 colocalizes with CHP1
in both HEK293 cells and myocytes, indicating that NHE1 is
available for the interaction with both proteins (Kobayashi et al.,
2015). It is, therefore, possible that the interaction of NHE1 with
tescalcin is either weaker than that with CHP1 in specific cellular
environments, or it might depend on thus far unidentified regulatory
mechanisms.
Most experiments on NHE1–tescalcin binding have been
performed by using recombinant proteins. However, recent
evidence is suggestive of an association between endogenous
tescalcin and NHE1 (Man et al., 2014). Here, the knockdown of
tescalcin in acute myeloid leukemia (AML) cell lines resulted in a
reduction of pH by ∼0.15 units. Given that pharmacological
blockade of NHE1 eliminated the effect of tescalcin knockdown,
the authors attributed this reduction in pH to the loss of interaction
between tescalcin and NHE1. These results are consistent with the
tescalcin-mediated activation of NHE1 that has been reported
previously in transfected cell models (Zaun et al., 2008).
COP9 signalosome
Another yeast two-hybrid screen using tescalcin as bait identified
subunit 4 of the COP9 signalosome (CSN4, encoded by COPS4) as
a binding partner of tescalcin (Levay and Slepak, 2014). The COP9
signalosome (CSN) is an evolutionary conserved complex
composed of eight subunits (CSN1–CSN8, encoded by GPS1 and
COPS2–COPS8) that has substantial similarity to the 26S
proteasome. CSN was first discovered as a negative regulator of
photomorphogenesis in Arabidopsis thaliana, and to date, many
studies have established its essential role in the normal development
of all eukaryotes. The CSN is a modulator of the cell cycle, DNA
repair, MAPK and steroid hormone signaling, axonal guidance and
other vital cellular processes (Kato and Yoneda-Kato, 2009; Wei
et al., 2008). At the mechanistic level, this broad range of biological
functions involves protein phosphorylation, gene transcription, and
protein degradation through cullin–RING–E3 ubiquitin ligases
(Kato and Yoneda-Kato, 2009; Wei et al., 2008). More than 50
proteins have been shown to interact with CSN subunits, but there
are only two binding partners of CSN4: torsinA (also known as
torsin-1A) (Granata et al., 2011), a poorly understood ATPase
known for its localization in endoplasmic reticulum and association
with movement disorders (Rose et al., 2015) and tescalcin.
Tescalcin specifically binds to CSN4 through its proteasome-
Cop9-eIF3 (PCI) domain in a Ca2+-dependent manner; this was
shown by using purified recombinant proteins in a yeast two-hybrid
system and a luciferase reporter assay in transfected HEK293 cells
(Levay and Slepak, 2014). CHP1 and CHP2 do not interact with the
COP9 signalosome in the same assays, which distinguishes
tescalcin from its closest homologs. According to deletion
mutagenesis, the interaction with CSN4 requires the unique
C-terminus of tescalcin (Levay and Slepak, 2014). Tescalcin can
also interact with CSN5 (also known as Jab1; Wei et al., 2008),
although this interaction is weaker than that with CNS4, whereas it
does not interact with any of the other CSN subunits. Importantly,
we have shown that knockdown of tescalcin in human
erythroleukemia HEL cells increases CSN activity. This increase
correlates with a negative effect on the ability of these cells to
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undergo induced differentiation and results in a change in the
expression levels of p53 and the c-Jun transcription factors, which
control a multitude of genes involved in cell cycle and
differentiation (Levay and Slepak, 2014).
GSK3
A recent comprehensive study showed that tescalcin inhibits GSK3
(Kobayashi et al., 2015), a Ser/Thr protein kinase involved in a
multitude of cellular functions that range from proliferation and
apoptosis to migration and metabolism (see e.g. Doble and
Woodgett, 2003; Rayasam et al., 2009). The original observation
of Kobayashi et al. was that adenovirus-mediated knockdown of
tescalcin resulted in hypertrophy of cultured neonatal ventricular
myocytes (NRVMs) (Kobayashi et al., 2015). Here, the extent of
cell enlargement was comparable to that caused by phenylephrine or
IGF-1, and was accompanied by upregulation of atrial natriuretic
peptide (ANP), a factor secreted by cardiac myocytes and one of the
markers of pathologic heart hypertrophy and other conditions (Song
et al., 2015). The magnitude of this effect demonstrated the
importance of tescalcin in regulation of NRVM size and gene
expression.
With regard to the molecular mechanisms underlying tescalcin
function, Kobayashi et al. observed an approximately threefold
increase in the phosphorylation of GSK3α and GSK3β at Ser9 upon
knockdown of tescalcin. In contrast, overexpression of tescalcin in
NRVMs inhibited stimulus-induced hypertrophy and blocked both
basal and insulin-induced GSK3 phosphorylation. Some of these
mechanisms were recapitulated in HEK293 cells, where expression
of GFP-fused tescalcin reduced insulin-induced phosphorylation of
GSK3 isoforms. This effect was selective for tescalcin, as under the
same conditions, CHP1 did not influence GSK3 phosphorylation.
Importantly, neither tescalcin nor CHP1 affect the phosphorylation
of AKT, one of the regulators of GSK3. Given that AKT-mediated
phosphorylation at Ser9 inhibits GSK3 activity, these results
showed that tescalcin is a selective inhibitor of GSK3. Moreover,
in a convincing series of co-immunoprecipitation and other
biochemical assays on NRVMs and co-transfected HEK293 cells,
Kobayashi et al. also demonstrated that tescalcin can form
complexes with either GSK3 or AKT. These results suggest that
the effect of tescalcin on GSK3 phosphorylation is mediated by its
direct binding to AKT and/or GSK3; however, participation of
another protein(s) in the tescalcin–GSK3 interaction cannot be ruled
out at this point. By using the Ca2+-binding-defective D123A
tescalcin mutant, Kobayashi et al. showed that Ca2+ is not required
for its interactions with these kinases and/or its inhibition of GSK3
activity (Kobayashi et al., 2015).
Taken together, these findings clearly show that tescalcin can
bind to and influence the activities of NHE1, the CSN and AKT and/
or GSK3 (Fig. 2). Tescalcin has also been found to block the
activation of calceneurin B by calmodulin in vitro (Gutierrez-Ford
et al., 2003), as well as to bind to G protein-coupled receptor kinase
2 in yeast two-hybrid experiments (J. Benovic, personal
communication). However, these latter findings have not yet been
confirmed by additional work. Regarding the selectivity of
tescalcin–effector interactions and the role of Ca2+, studies have
shown that tescalcin is the only member of the CHP family capable
of binding to GSK3 and CSN4, whereas NHE1 can also bind to
CHP1 and CHP2. Ca2+ is important for the interaction of tescalcin
with CSN4 and NHE1, but not with GSK3.
It is not unusual for a Ca2+ sensor to interact with several
effectors, for example, calmodulin is known to regulate dozens of
proteins, typically through distinct α-helical motifs present in its
targets. Additional experiments are needed to understand the
molecular basis of the interaction between tescalcin and its target
proteins, which are all structurally and functionally unrelated. It is
reasonable to assume that the binding sites for tescalcin in CSN4 (or
CSN5) and AKT and/or GSK3 are different from those in NHE1, as
the latter can distinguish between tescalcin and CHP1 or CHP2.
Considering the affinity of tescalcin for Ca2+, we can also speculate
that at very high Ca2+ concentrations, tescalcin will bind to its target
as a monomer, whereas its dimeric form, which presumably has
higher affinity for Ca2+, might interact with additional effectors. It is
also possible that the Ca2+-free EF-hand of tescalcin could function
as a protein docking module in the interaction with GSK3, similar to
that of Nkd proteins that regulate Wnt pathway (Wharton et al.,
2001).
The tescalcin targets also have different subcellular localization.
NHE1 is localized at the plasma membrane, whereas GSK3 and
CSN can be found in the cytoplasm and the nucleus. However, as
we discuss below, tescalcin is found throughout the cell, supporting
the possibility that these interactions occur in situ. Moreover,
although its effectors are expressed ubiquitously, the expression of
tescalcin is tightly regulated, suggesting that its ability to regulate
NHE1 
GSK3 
Transcription factors: 
Ets, c-Jun, p53  
Cell cycle 
Cop9 
CSN 
ERK1/2 
Differentiation 
? 
Abnormal development Cancer 
AKT 
PKC 
p27Kip1
pHi
InsR 
Tescalcin 
RTK 
Cell size 
Ubiquitylation 
Ca2+ ? 
? 
? 
Na+ 
H+ 
Up- or down- 
regulation 
Fig. 2. Protein–protein interactions and biological activities of tescalcin.
Tescalcin modulates the activities of NHE1, the Cop9 signalosome and the
AKT–GSK3 axis. It interacts directly with NHE1, increasing its stability and the
rate of exchange of Na+ for H+ ions, which leads to elevation of intracellular pH
(pHi). Tescalcin has also been shown to interact with the CSN4 (and CSN5)
subunit of the signalosome which affects many processes including
degradation of proteins involved in cell cycle. Finally, tescalcin interacts with
the protein kinases AKT and GSK3, which have multiple substrates and a
number of known mechanisms of activation, e.g. through insulin receptor
(InsR), which has been shown to activate GSK3 in a tescalcin-dependent
manner (see text). Each of these pathways has many downstream effectors,
including cell-type-specific transcription factors. The level of tescalcin
expression is regulated by ERK1/2 (brown arrow) through an unknown
mechanism; it can be up- or down-regulated depending on the cell type.
ERK1/2 can be activated by PKC, receptor tyrosine kinases (RTKs) and other
mechanisms. The interaction of tescalcin with NHE1 and CSN4, but not that
with AKT and/or GSK3, requires Ca2+. Depending on the cell type, the
physiological effects include cell cycle arrest and differentiation, or growth.
Furthermore, genetic evidence has implicated the tescalcin gene (TESC) in
cancer and developmental abnormalities (see text).
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the pathways described above is limited to certain cell types and
stages of development.
Subcellular localization and tissue distribution of tescalcin
According to fractionations of mouse heart or HeLa cells,
endogenous tescalcin partitions to soluble, membrane and
nuclear, but not to cytoskeletal, fractions (Gutierrez-Ford et al.,
2003). In addition, immunofluorescence microscopy of tescalcin
that had been overexpressed in PC12, HeLa or CHO-K1 cells
detected it throughout the cell, but concentrated in the perinuclear
region. Here, mutations that prevent Ca2+ binding or
N-myristoylation, or manipulations of cellular Ca2+ with BAPTA-
AM or ionomycin did not alter the localization of tescalcin
(Gutierrez-Ford et al., 2003). Furthermore, in the myelogenous
leukemia cell line K562, we found stably expressed tescalcin in the
nucleus (Levay and Slepak, 2007). In a clone of CHO cells that lack
NHE1, Myc-tagged tescalcin is distributed evenly throughout the
cytoplasm, with an increase in its concentration in and around the
nucleus (Zaun et al., 2008). However, when these cells are
transfected with NHE1, the bulk of tescalcin redistributes to the
plasma membrane. More recent work addressing endogenous
tescalcin in cardiac myocytes has shown that it is spread uniformly
throughout the cytoplasm and nucleus (Kobayashi et al., 2015).With
respect to its cellular localization, tescalcin is similar toCHP1,which
has been shown to translocate between the nucleus, cytoplasm and
plasma membrane (Jiménez-Vidal et al., 2010).
The expression levels of tescalcin vary considerably between
tissues, and in what appears to be unique for tescalcin compared
with CHP1 and CHP2, changes dramatically during development.
CHP1 is broadly expressed and the most conserved member of the
family across many species. CHP2 is found in normal intestinal
epithelia, but is preferentially expressed in tumor tissues, for
example in human liver cancer specimens (Inoue et al., 2003; Li
et al., 2008). Moreover, overexpression of CHP2 increases the
oncogenic potential of stably transfected HEK293 cells following
their inoculation into nude mice (Li et al., 2008). In contrast to
CHP1, CHP2 and tescalcin are only found among vertebrates (Di
Sole et al., 2012).
In mouse embryos, the highest concentration of tescalcin mRNA
is observed in the testis, hence the name of the protein (Perera et al.,
2001). However, in adult mouse, protein levels are highest in the
stomach, heart and brain, with only a minor expression in testis
(Gutierrez-Ford et al., 2003). Human tescalcin has a localization
pattern that is similar to mice, with low mRNA levels in adult testes
and abundant expression in the adult heart. In addition, the protein
levels in the adult rat heart (ventricles and atria) are considerably
higher than in the brain (Kobayashi et al., 2015). Interestingly,
tescalcin is not present in skeletal or smooth muscle at all
(Gutierrez-Ford et al., 2003), suggesting that is has a cardiac-
myocyte-specific function or that it could be involved in the
differentiation of muscle cells. Tescalcin mRNA has also been
found in human pancreas, bone marrow, salivary and adrenal
glands, and placenta (Gutierrez-Ford et al., 2003). Furthermore,
antibodies against tescalcin have detected the endogenous protein in
a number of tumor cell lines, pointing to a potential link to cancer
(Fan et al., 2015; Gutierrez-Ford et al., 2003; Kang et al., 2014;
Levay and Slepak, 2010, 2014).
A recent survey of the Allen Brain Atlas examined gene
expression profiles of the entire EF-hand superfamily (Girard
et al., 2015). There is no expression of CHP2 and no data for CHP1,
but tescalcin mRNA has been found to be present in many regions,
including the main olfactory bulb, basal ganglia and amygdala.
Strong expression of tescalcin is also found in the hippocampus,
which is particularly interesting in light of the genetic linkage
of the TESC gene with human central nervous system (CNS)
abnormalities (see below). Obviously, detailed analysis of the
dissected regions are needed to validate the Brain Atlas data and to
further dissect the physiological roles of tescalcin and how they are
linked to human disorders.
The role of tescalcin in cell differentiation and proliferation
Induced in vitro differentiation of the hematopoetic cell lines HL60
and K562 results in a dramatic change in tescalcin expression,
which occurs at either the transcription or post-transcriptional level
(Levay and Slepak, 2007, 2010). Experimental manipulation of
tescalcin expression highlights its role in the pathways that control
differentiation in these cell lines, as well as in primary
megakaryocytes. For instance, tescalcin overexpression in K562
cells leads to spontaneous polyploidization, a reduction in growth
rate and the appearance of megakaryocytic markers such as GPIIb
integrin. At the same time, knockdown of tescalcin by RNA
interference significantly slows down differentiation that is induced
by factors such as phorbol 12-myristate 13-acetate (PMA), an
activator of protein kinase C (PKC) (Levay and Slepak, 2007).
However, a later study that generated a tescalcin knockout in mice
did not detect changes in the amount of megakaryocytes and
platelets (Ukarapong et al., 2012). To explain the conflicting data,
the authors speculate that CHP1 and/or CHP2 could compensate for
the lack of tescalcin, or that their genetic knockout was incomplete
and allowed for the expression of a partial protein (Ukarapong et al.,
2012). Another possible explanation is that Ukarapong et al. might
have only analyzed the adult mice. Thus, any effects of tescalcin
knockout during development or in response to stress such as blood
loss, which restores the megakaryocyte population, might have been
missed. In fact, tescalcin knockdown does not completely block
megakaryocytic differentiation, but instead delays it considerably
(Levay and Slepak, 2007).
The exact mechanism of how tescalcin affects the differentiation
of hematopoetic precursors has not been determined. Tescalcin does
not have a DNA-binding domain and is not a transcription factor
itself. What is known is that human K562 or HEL cells can be
induced to differentiate along the megakaryocytic lineage through a
cascade that involves activation of PKC, ERK1 and ERK2 (ERK1/2,
also known as MAPK3 andMAPK1) and upregulation of Fli-1, Ets-
1 and Ets-2 factors (Levay and Slepak, 2007). Activation of
this pathway drives the expression of megakaryocyte-specific genes
and coincides with a several-fold increase in tescalcin level.
Importantly, after TESC knockdown, the transcription factors Ets-1
and Fli-1 can no longer be detected at either the protein or mRNA
level, even in PMA-treated cells. This indicates that tescalcin acts
upstream of the Ets transcription factors. Pharmacological blockade
of ERK1/2 or PKC prevents upregulation of tescalcin, indicating that
tescalcin acts downstream of ERK1/2 (Fig. 2). Although the
molecular mechanism of tescalcin-mediated upregulation of Ets
transcription factors has not been elucidated, it is possible that GSK3
and/or the COP9 signalosome play a role in this process. Given that
the expression of other transcription factors, such as GATA1 or
MafB, remains unchanged, it is clear that this mechanism is selective
toward particular transcription factors, and does not influence gene
transcription in general (Levay and Slepak, 2007).
Ets factors do not only participate in hematopoiesis (Ciau-Uitz
et al., 2013) but also have a role in normal development and
pathology of cardiovascular and endocrine systems (Dittmer, 2015;
Gutierrez-Hartmann et al., 2007; Meadows et al., 2011); this might,
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at least in part, explain the TESC-associated conditions affecting
the CNS and other organs (see below). Tescalcin is also involved in
the differentiation and maturation of granulocytes, a process that is
also mediated by ERK1/2 signaling (Levay and Slepak, 2010). It
is important to note that although tescalcin is upregulated in
some differentiation pathways (e.g. in granulocytes or in the
developing heart), it is downregulated in others (macrophages,
testes) (Gutierrez-Ford et al., 2003; Kobayashi et al., 2015; Levay
and Slepak, 2010). Consistent with its role in differentiation, recent
studies have implicated tescalcin in some developmental defects
and cancer, as discussed in the following sections.
The TESC gene in human abnormalities affecting the CNS
The TESC gene is localized in 12th human chromosome and
contains eight exons. Genome-wide association analysis has
revealed a significant linkage between the single-nucleotide
polymorphism (SNP) rs7294919 on chromosome 12q24 and
reduced hippocampal volume. This SNP appears to regulate the
transcriptional activity of the TESC gene (Stein et al., 2012). This
work was extended by Dannlowski et al. who used different
imaging methods and confirmed the association of the TESC gene
SNPs with the reduction of volume in the gray matter of
hippocampal formation, an area of relatively high tescalcin
expression (Dannlowski et al., 2015). The authors also
demonstrated an interaction of tescalcin with the rs2299403
variant of the RELN gene, encoding reelin, through an unknown
molecular mechanism. Reelin, a secreted glycoprotein involved in
neuronal migration and signaling, has been shown to affect higher
cognitive processes and to play a role in schizophrenia and bipolar
disorder (Guidotti et al., 2016).
Another group has described a patient with symptoms of
developmental delay and other anomalies related to hemizygous
deletion at the 12q telomere, which encompasses at least 52
annotated genes. Given that most similar patients had male genitalia
abnormalities, the authors suggested that the TESC gene was crucial
for the defective development (Al-Zahrani et al., 2011). TESC
mutations are also present among the genes associated with
intellectual disability in a cohort of psychiatric patients in the
Dagestan region of southern Russia (Bulayeva et al., 2015).
Considering the role of tescalcin in cell differentiation and the
regulation of Ets transcription factors (Levay and Slepak, 2007), the
link between TESC mutations and brain development could be
potentially explained by disrupted expression of multiple genes that
are regulated by tescalcin-mediated pathway(s). Obviously, GSK3
and NHE1 are also involved in multiple fundamentally important
pathways, and any aberration in the interaction between tescalcin
and these factors is likely to also have effects in the CNS.
Tescalcin and cancer
Alterations in the expression and copy number of the TESC gene
have also been linked to radiation-induced papillary thyroid
carcinoma (PTC) in pediatric patients that have been exposed to
radioactive fallout from the Chernobyl disaster (Stein et al., 2010).
In particular, the authors reported increases in the copy numbers of
the subtelomeric and telomeric regions of chromosome 12q. By
comparing gene expression between sporadic and radiation-induced
PTC samples, they identified over 100 genes that are uniquely
expressed in the tumors originating from Chernobyl, with the TESC
gene being one of the genes that showed the highest increase in
expression.
Other groups around the world have also recently implicated
tescalcin in different cancers. For example, one study has shown that
the TESC gene is expressed in human colorectal cancer (CRC)
tissues, but not in normal mucosa and premalignant lesions (Kang
et al., 2014). Here, the level of TESC expression in cancer tissues
correlated with the pathological characteristics of patients with
CRC. According to this study, patients with high TESC expression
are more likely to have a shorter survival period than patients with
low expression. As there are currently no efficient prognostic factors
for CRC, the expression levels of tescalcin in the tumor could
represent a diagnostic marker. In addition, the authors also reported
significantly higher levels of tescalcin in the serum of CRC patients
compared to control individuals (Kang et al., 2014). However, in
our opinion, these results should be viewed with caution because it
is unclear how tescalcin, as an intracellular protein of low
abundance, could be detected in serum.
As mentioned above, a link between AML pathogenesis and the
interaction of tescalcin with NHE1 has been found in AMLMOLM-
13 and MV4-11 cell lines, where tescalcin knockdown leads to
intracellular acidosis and apoptosis (Man et al., 2014). Furthermore,
TESC is one of the genes that is upregulated when these leukemia
cells develop resistance to sorafenib, a tyrosine kinase inhibitor that
has been approved for treatment of some types of cancer but is
unable to fully inhibit subsequent leukemia progression. The
authors found that pharmacological inhibition of NHE1 by a
derivative of the known diuretic amiloride results in cell
acidification and apoptosis, and repression of resistance of AML
to sorafenib. The authors conclude that upregulation of tescalcin
causes soranfenib resistance through an increase in NHE1 activity
and subsequent rise in the intracellular pH, which favors cell
survival and growth (Man et al., 2014).
Another recent study has observed an upregulation of tescalcin in
melanoma and colon tumors, as well as in gastric and colorectal
tumor cell lines (Fan et al., 2015). In the course of their studies, the
authors identified an interesting epigenetic mechanism underlying
the increase of TESC expression. They found that binding of the
long non-coding RNA ROR to the TESC promoter prevents access
of the histone methyltransferase G9A (also known as EHMT2),
thereby counteracting histone H3K9-methylation-mediated gene
repression (Fan et al., 2015).
Taken together with the insights in its role in cell differentiation,
the rapidly growing evidence shows that aberrant expression of
tescalcin plays a role in many types of cancer, which identifies it as a
potential oncotarget.
Conclusions
Tescalcin is an EF-hand Ca2+-binding protein with tissue-specific
and developmentally regulated expression. At the molecular level,
tescalcin interacts with NHE1, GSK3 and the COP9 signalosome
(Fig. 2). It has also been shown to link activation of ERK1/2 with
Ets and a few other transcription factors through an as-yet-unknown
mechanism. Thus, not unlike its distant and much more renowned
EF-hand relative calmodulin, it appears to have the ability to
regulate diverse protein targets. In contrast to calmodulin, tescalcin
is involved in the regulation of relatively slow cellular processes,
such as cell differentiation and proliferation. Consistent with this
notion, human genetics and gene expression profiling studies have
uncovered correlations between abnormal tescalcin expression and
brain developmental deficiencies and cancer. However, we have
only just begun unraveling the molecular mechanisms underlying
these abnormalities. As with other new gene products, this
understanding will require research at the molecular, cellular and
whole organism levels. More information on protein–protein
interactions of tescalcin, the role of Ca2+ and its unique structural
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elements will be necessary to elucidate the contribution of this
protein in signaling networks. Precise characterization of the nature
of TESC mutations will also shed more light on the mechanisms of
tescalcin involvement in human pathology.
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